T0	Participants 43 95	patients with chronic obstructive pulmonary disease:
T1	Participants 728 801	435 adults with stable, symptomatic, smoking-related COPD were randomized
T2	Participants 1184 1307	79 patients with serious adverse events (SAEs), 43 (14.8%) in the sibenadet pMDI group and 36 (24.8%) in the placebo group.